학술논문

Neurosarcoidosis-related intracranial haemorrhage: three new cases and a systematic review of the literature.
Document Type
Article
Source
European Journal of Neurology. Jan2013, Vol. 20 Issue 1, p71-78. 8p. 5 Black and White Photographs.
Subject
*INTRACRANIAL hematoma
*META-analysis
*IMMUNOLOGY
*NEUROLOGICAL disorders
*STROKE
Language
ISSN
1351-5101
Abstract
Background and purpose Intracranial haemorrhage in neurosarcoidosis (NS-ICH) is rare, poorly understood and the diagnosis of NS may not be immediately apparent. Methods The clinical features of three new NS-ICH cases are described including new neuropathological findings and collated with cases from a systematic literature review. Results Cases: (i) A 41-year-old man with headaches, hypoandrogenism and encephalopathy developed a cerebellar haemorrhage. He had neuropathological confirmation of NS with biopsy-proven angiocentric granulomata and venous disruption. He responded to immunosuppressive therapy. (ii) A 41-year-old man with no history of hypertension was found unconscious. A subsequently fatal pontine haemorrhage was diagnosed. Liver biopsy revealed sarcoid granulomas. (iii) A 36-year-old man with raised intracranial pressure headaches presented with a seizure and a frontal haemorrhage. Hilar lymph node biopsy confirmed sarcoidosis, and he was treated successfully. Systematic review: Twelve other published cases were identified and collated with our cases. Average age was 36 years and M:F = 2.3:1; 46% presented with neurological symptoms and 31% had CNS-isolated disease. Immediate symptoms of ICH were acute/worsening headache or seizures (60%). ICH was supratentorial (62%), infratentorial (31%) or subarachnoid (7%). Forty percent had definite NS, 53% probable NS and 7% possible NS (Zajicek criteria). Antigranulomatous/immunosuppressive therapy regimens varied and 31% died. Conclusions This series expands our knowledge of the pathology of NS-ICH, which may be of arterial or venous origin. One-third have isolated NS. Clinicians should consider NS in young-onset ICH because early aggressive antigranulomatous therapy may improve outcome. [ABSTRACT FROM AUTHOR]